That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 ... Novo Nordisk now faces the challenge of navigating an increasingly competitive landscape, with emerging alternatives threatening ...

The stock remains well-positioned to rebound ... increasing by 22% from the prior year. Novo Nordisk now faces the challenge of navigating an increasingly competitive landscape, with emerging ...